294 related articles for article (PubMed ID: 25395255)
1. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.
Suntjens EB; Smid BE; Biegstraaten M; Dreschler WA; Hollak CE; Linthorst GE
J Inherit Metab Dis; 2015 Mar; 38(2):351-8. PubMed ID: 25395255
[TBL] [Abstract][Full Text] [Related]
2. Inner ear involvement in Fabry disease: Clinical and audiometric evaluation of a large cohort of patients followed in a reference centre.
Rodrigues J; Azevedo O; Sousa N; Cunha D; Mexedo A; Fonseca R
Eur J Med Genet; 2018 Jun; 61(6):341-347. PubMed ID: 29307789
[TBL] [Abstract][Full Text] [Related]
3. Hearing loss in children with Fabry disease.
Suntjens E; Dreschler WA; Hess-Erga J; Skrunes R; Wijburg FA; Linthorst GE; Tøndel C; Biegstraaten M
J Inherit Metab Dis; 2017 Sep; 40(5):725-731. PubMed ID: 28567540
[TBL] [Abstract][Full Text] [Related]
4. Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy.
Sergi B; Conti G; Paludetti G;
Acta Otorhinolaryngol Ital; 2010 Apr; 30(2):87-93. PubMed ID: 20559478
[TBL] [Abstract][Full Text] [Related]
5. Hearing improvement in patients with Fabry disease treated with agalsidase alfa.
Hajioff D; Goodwin S; Quiney R; Zuckerman J; MacDermot KD; Mehta A
Acta Paediatr Suppl; 2003 Dec; 92(443):28-30; discussion 27. PubMed ID: 14989462
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
7. Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy.
Palla A; Hegemann S; Widmer U; Straumann D
J Neurol; 2007 Oct; 254(10):1433-42. PubMed ID: 17934877
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
9. [Auditory and vestibular findings in Fabry disease: a study of 25 patients].
Pichon M; Lidove O; Roudaire ML; Barry B; Herman P; Gobert D; Pasqualoni E; Compain C; Chauveheid MP; Papo T
Rev Med Interne; 2012 Jul; 33(7):364-9. PubMed ID: 22365473
[TBL] [Abstract][Full Text] [Related]
10. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females.
Conti G; Sergi B
Acta Paediatr Suppl; 2003 Dec; 92(443):33-7; discussion 27. PubMed ID: 14989464
[TBL] [Abstract][Full Text] [Related]
11. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.
Hajioff D; Hegemann S; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A
Eur J Clin Invest; 2006 Sep; 36(9):663-7. PubMed ID: 16919050
[TBL] [Abstract][Full Text] [Related]
12. Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY.
Asquier-Khati A; Mauhin W; Michel G; Gendre A; Durant C; Lavigne C; Maillard H; Lacombe D; Willems M; Lidove O; Masseau A
Eur Arch Otorhinolaryngol; 2022 Mar; 279(3):1639-1644. PubMed ID: 34825971
[TBL] [Abstract][Full Text] [Related]
13. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
14. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.
Anderson LJ; Wyatt KM; Henley W; Nikolaou V; Waldek S; Hughes DA; Pastores GM; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):969-78. PubMed ID: 24831586
[TBL] [Abstract][Full Text] [Related]
16. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.
Hajioff D; Enever Y; Quiney R; Zuckerman J; Mackermot K; Mehta A
J Inherit Metab Dis; 2003; 26(8):787-94. PubMed ID: 14739683
[TBL] [Abstract][Full Text] [Related]
17. Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.
Barba-Romero MÁ; Pintos-Morell G
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27886142
[TBL] [Abstract][Full Text] [Related]
18. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.
Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M
Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518
[TBL] [Abstract][Full Text] [Related]
19. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
